Drug intelligence / Profile preview

dositinib mesylate

Development stage: Unknown
Lead developer: Genuine Biotech
Modality: Small Molecules
Administration: Oral

Overview

Dositinib mesylate is an orally bioavailable small molecule inhibitor of the epidermal growth factor receptor (EGFR), developed by Henan Genuine Biotech Co., Ltd. It is specifically designed to target EGFR mutations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). By inhibiting the tyrosine kinase activity of mutated EGFR, dositinib blocks downstream signaling pathways that drive tumor cell proliferation and survival. The drug is currently being evaluated in Phase I/II clinical trials to determine its safety, pharmacokinetics, and preliminary efficacy as a monotherapy and in combination with other agents such as GEN-725.

Other names: dositinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on dositinib mesylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dositinib mesylate.

Explore the full profile